These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27997976)

  • 1. The Microbiome: What Will the Future Hold?
    Monsour HP; Quigley EM
    Semin Liver Dis; 2016 Sep; 36(4):354-359. PubMed ID: 27997976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Dysbiosis for the Treatment of Liver Disease.
    Anand G; Zarrinpar A; Loomba R
    Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal microbiota in liver disease.
    Haque TR; Barritt AS
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
    Vemuri RC; Gundamaraju R; Shinde T; Eri R
    Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Human Gut Microbiome in Liver Diseases.
    Davis BC; Bajaj JS
    Semin Liver Dis; 2017 May; 37(2):128-140. PubMed ID: 28564721
    [No Abstract]   [Full Text] [Related]  

  • 8. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.
    Distrutti E; Monaldi L; Ricci P; Fiorucci S
    World J Gastroenterol; 2016 Feb; 22(7):2219-41. PubMed ID: 26900286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
    Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
    Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?
    Berg D; Clemente JC; Colombel JF
    Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):781-95. PubMed ID: 25665875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiome approaches to treat obesity in humans.
    Bianchi F; Duque ALRF; Saad SMI; Sivieri K
    Appl Microbiol Biotechnol; 2019 Feb; 103(3):1081-1094. PubMed ID: 30554391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies.
    West CE; Renz H; Jenmalm MC; Kozyrskyj AL; Allen KJ; Vuillermin P; Prescott SL;
    J Allergy Clin Immunol; 2015 Jan; 135(1):3-13; quiz 14. PubMed ID: 25567038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?
    Doré J; Multon MC; Béhier JM;
    Therapie; 2017 Feb; 72(1):21-38. PubMed ID: 28131442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease.
    Cho JA; Chinnapen DJF
    J Microbiol; 2018 Mar; 56(3):183-188. PubMed ID: 29492875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases.
    Singh B; Qin N; Reid G
    Inflamm Allergy Drug Targets; 2015; 14(2):84-93. PubMed ID: 26817477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction.
    Lechner S; Yee M; Limketkai BN; Pham EA
    Dig Dis Sci; 2020 Mar; 65(3):897-905. PubMed ID: 32020359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the microbiota in the management of gastrointestinal and liver disease.
    Quigley EM; Monsour HP
    Rev Gastroenterol Peru; 2013; 33(2):139-44. PubMed ID: 23838941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.
    Matijašić M; Meštrović T; Perić M; Čipčić Paljetak H; Panek M; Vranešić Bender D; Ljubas Kelečić D; Krznarić Ž; Verbanac D
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.
    Rossi M; Johnson DW; Morrison M; Pascoe EM; Coombes JS; Forbes JM; Szeto CC; McWhinney BC; Ungerer JP; Campbell KL
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):223-31. PubMed ID: 26772193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the microbiota in infectious diseases.
    Libertucci J; Young VB
    Nat Microbiol; 2019 Jan; 4(1):35-45. PubMed ID: 30546094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.